PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Christine Marie Utter sold 297 shares of the company’s stock in a transaction that occurred on Monday, January 7th. The shares were sold at an average price of $34.75, for a total transaction of $10,320.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of NASDAQ PTCT opened at $37.96 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.73 and a quick ratio of 2.61. The firm has a market capitalization of $1.89 billion, a PE ratio of -18.79 and a beta of 2.04. PTC Therapeutics, Inc. has a 1 year low of $20.21 and a 1 year high of $52.95.
PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.66). The firm had revenue of $53.59 million during the quarter, compared to analysts’ expectations of $70.56 million. PTC Therapeutics had a negative return on equity of 27.95% and a negative net margin of 30.61%. The business’s revenue for the quarter was up 28.0% on a year-over-year basis. During the same period last year, the company earned ($0.82) earnings per share. As a group, research analysts predict that PTC Therapeutics, Inc. will post -1.96 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc grew its stake in PTC Therapeutics by 7.5% during the third quarter. Legal & General Group Plc now owns 11,725 shares of the biopharmaceutical company’s stock valued at $550,000 after acquiring an additional 818 shares in the last quarter. Rehmann Capital Advisory Group purchased a new position in PTC Therapeutics during the third quarter valued at $59,000. Metropolitan Life Insurance Co. NY grew its stake in PTC Therapeutics by 13.5% during the second quarter. Metropolitan Life Insurance Co. NY now owns 14,769 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 1,753 shares in the last quarter. MetLife Investment Advisors LLC grew its stake in PTC Therapeutics by 9.6% during the second quarter. MetLife Investment Advisors LLC now owns 21,050 shares of the biopharmaceutical company’s stock valued at $710,000 after acquiring an additional 1,850 shares in the last quarter. Finally, First Republic Investment Management Inc. grew its stake in PTC Therapeutics by 30.0% during the third quarter. First Republic Investment Management Inc. now owns 9,178 shares of the biopharmaceutical company’s stock valued at $431,000 after acquiring an additional 2,118 shares in the last quarter. 92.55% of the stock is owned by institutional investors.
PTCT has been the subject of a number of research reports. ValuEngine cut shares of PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 6th. William Blair reissued a “buy” rating on shares of PTC Therapeutics in a research note on Tuesday, November 6th. Credit Suisse Group set a $55.00 price objective on shares of PTC Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 5th. Cantor Fitzgerald reissued a “buy” rating and issued a $61.00 price objective on shares of PTC Therapeutics in a research note on Monday. Finally, Barclays reduced their price objective on shares of PTC Therapeutics from $43.00 to $40.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 6th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $45.63.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.
See Also: Why is insider trading harmful?
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.